GRI Bio reports positive interim biomarker data from Phase 2a IPF study; IDMC recommends continuation

GRI Bio, Inc.

6-week interim data from Phase 2a study of GRI-0621 in IPF show reduced fibrogenesis and increased fibrolysis in treated patients.
IDMC recommended study continue as planned; no safety concerns seen to date.
Phase 2a study fully enrolled; topline data expected Q3 2025.
GRI-0621 patients demonstrated increased basement membrane remodeling and potential repair mechanism vs control.
Additional pulmonary function test results expected in coming weeks; flow cytometry and gene expression data later.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.